Laverock Therapeutics expands seed funding and announces key milestone progress
Laverock closes additional seed funding led by Calculus
Laverock closes additional seed funding led by Calculus
Tagomics has been awarded £860k in funding from Innovate UK’s Biomedical Catalyst programme to develop a novel diagnostic test for colorectal cancer. The grant forms part of a £1.2M project.
Calculus first invested in Rotageek in 2020 as part of its Series B funding round, co-investing alongside Gresham House Ventures, and since participated in follow-on rounds totalling £3 million in investment from its VCT and EIS Funds.
Innovative booking, marketing, CRM, and loyalty platform continues rapid growth
Hargreaves’ service will debut with a group of five VCTs including the Calculus VCT.
Calculus Investor Relations team members Matthew Moynes and Oliver Warren are joined by Investment Director and healthcare specialist Liz Klein to speak about EIS investing and how it can help mitigate a high tax burden.
Five years after entering the UK screen industries with the launch of the Creative Content EIS Fund, Calculus Capital CEO John Glencross reflects on how its investments in six indie production companies are performing.